BR112016004911A2 - Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado - Google Patents

Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado

Info

Publication number
BR112016004911A2
BR112016004911A2 BR112016004911A BR112016004911A BR112016004911A2 BR 112016004911 A2 BR112016004911 A2 BR 112016004911A2 BR 112016004911 A BR112016004911 A BR 112016004911A BR 112016004911 A BR112016004911 A BR 112016004911A BR 112016004911 A2 BR112016004911 A2 BR 112016004911A2
Authority
BR
Brazil
Prior art keywords
acute liver
liver failure
secreted
cysteine
acidic
Prior art date
Application number
BR112016004911A
Other languages
English (en)
Inventor
Peixoto Estanislao
C Atorrasagasti María
Daniel Mazzolini Guillermo
Aquino Jorge
Podhjacer Osvaldo
Original Assignee
Inis Biotech Llc
Asoc Civil De Estudios Superiores Aces
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Fundacion Inst Leloir Fil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inis Biotech Llc, Asoc Civil De Estudios Superiores Aces, Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Fundacion Inst Leloir Fil filed Critical Inis Biotech Llc
Publication of BR112016004911A2 publication Critical patent/BR112016004911A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MÉTODO PARA PREVENIR OU TRATAR INSUFICIÊNCIA HEPÁTICA AGUDA OU LESÃO HEPÁTICA AGUDA, COMPOSIÇÃO FARMACÊUTICA, USO DE UM AGENTE, AGENTE, CONSTRUTO GENÉTICO E SIRNA. A invenção refere-se à identificação de Proteína Secretada, Acídica e Rica em Cisteína (SPARC) como um novo alvo terapêutico em pacientes com hepatite fulminante permitindo o desenvolvimento de uma estratégia destinada a proteger o fígado de lesão. A invenção concerne o tratamento de insuficiência hepática aguda ou hepatite fulminante por administração a um paciente dele necessitado de um agente que inibe ao menos parcialmente a expressão de SPARC e/ou interfere com sua função biológica.
BR112016004911A 2013-09-05 2014-09-05 Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado BR112016004911A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874191P 2013-09-05 2013-09-05
PCT/IB2014/064295 WO2015033309A2 (en) 2013-09-05 2014-09-05 Sparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure

Publications (1)

Publication Number Publication Date
BR112016004911A2 true BR112016004911A2 (pt) 2017-09-05

Family

ID=51842697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004911A BR112016004911A2 (pt) 2013-09-05 2014-09-05 Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado

Country Status (5)

Country Link
US (1) US10385114B2 (pt)
EP (1) EP3041861B1 (pt)
AR (1) AR099641A1 (pt)
BR (1) BR112016004911A2 (pt)
WO (1) WO2015033309A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113041262B (zh) * 2019-12-26 2023-08-04 中国科学院分子细胞科学卓越创新中心 内胚层干细胞在预防和/或治疗肝脏免疫失调疾病中的应用
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
CA2721453A1 (en) 2008-04-14 2009-10-22 Abraxis Bioscience Llc Sparc anti-inflammatory activity and uses thereof
PT2296672E (pt) 2008-06-11 2016-01-22 Fresenius Medical Care De Gmbh Meio condicionado de células progenitoras de fígado

Also Published As

Publication number Publication date
US10385114B2 (en) 2019-08-20
AR099641A1 (es) 2016-08-10
WO2015033309A3 (en) 2015-11-12
EP3041861A2 (en) 2016-07-13
EP3041861B1 (en) 2019-03-27
WO2015033309A2 (en) 2015-03-12
US20160201057A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
CL2019000268A1 (es) Composición de cannabis.
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112018003898A2 (pt) material auxiliar para aplicação no tecido de cólon
AR105712A1 (es) Composiciones de insulina de rápida acción
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
BR112015016189A8 (pt) usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]